Inventiva (NASDAQ:IVA) Shares Gap Down - Time to Sell?

Key Points

• Inventiva S.A. shares gapped down from a previous close of $6.02 to an opening price of $5.73, with the last traded price at $5.71 and a trading volume of 22,584 shares.
• Several Wall Street analysts have positive outlooks for Inventiva, with a consensus rating of "Moderate Buy" and an average price target of $14.83, up to a high of $26.00 from Piper Sandler.
• A recent investment by Creative Planning marks an increase in institutional ownership, which now comprises 19.06% of Inventiva's stock, reflecting greater confidence among institutional investors.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report)'s share price gapped down prior to trading on Tuesday . The stock had previously closed at $6.02, but opened at $5.73. Inventiva shares last traded at $5.71, with a volume of 22,584 shares changing hands.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on IVA. HC Wainwright began coverage on shares of Inventiva in a research report on Wednesday, September 3rd. They set a "buy" rating and a $20.00 price target for the company. Piper Sandler began coverage on shares of Inventiva in a research report on Wednesday, August 27th. They set an "overweight" rating and a $26.00 price target for the company. Finally, Guggenheim increased their price target on shares of Inventiva from $9.00 to $13.00 and gave the company a "buy" rating in a research report on Tuesday, September 2nd. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $14.83.

Inventiva Price Performance

The company's 50-day moving average price is $4.41 and its 200 day moving average price is $3.67.

Institutional Investors Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Creative Planning bought a new position in Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The firm bought 10,000 shares of the company's stock, valued at approximately $32,000. Hedge funds and other institutional investors own 19.06% of the company's stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.